OCTIMET oncology was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen. Headed by Dr. Timothy Perera (CEO), OCTIMET has licensed highly selective MET kinase inhibitors with clean safety profiles from Janssen Pharmaceutica and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection.
View Top Employees from OCTIMET Oncology NV| Website | http://octimet.com |
| Revenue | $5 million |
| Funding | $12.1 million |
| Employees | 3 (1 on RocketReach) |
| Founded | 2016 |
| Address | Turnhoutseweg 30, Beerse, Flanders 2340, BE |
| Phone | +32 473 55 83 53 |
| Technologies |
JavaScript,
HTML,
Google Analytics
+6 more
(view full list)
|
| Industry | Biotechnology, Research Services, Pharmaceuticals, Science and Engineering, Healthcare, Medical, Health Care |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541713 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular OCTIMET Oncology NV employee's phone or email?
OCTIMET Oncology NV Questions
The OCTIMET Oncology NV annual revenue was $5 million in 2024.
1 people are employed at OCTIMET Oncology NV.
OCTIMET Oncology NV is based in Beerse, Flanders.
The NAICS codes for OCTIMET Oncology NV are [541713, 54171, 5417, 54, 541].
The SIC codes for OCTIMET Oncology NV are [873, 87].
